MoleMate cancer tester 'less accurate' than doctors' eyes

July 24, 2012

(Medical Xpress) -- Differentiating melanomas from other pigmented skin lesions in primary care is challenging - but a device used by Australian and British doctors to determine whether a patient has a melanoma has been found to be less accurate than GPs using their eyes and judgment, according to a researcher at The University of Western Australia. 

In fact, MoleMate does not improve the diagnosis of but results in more patients with benign being referred for investigation and treatment, according to Winthrop Professor Jon Emery, Chair of General Practice and Head of the School of Primary Aboriginal and Rural Health Care. Professor Emery, who also holds an adjunct position as Senior Clinical Research Associate at Cambridge University in the UK, works on cancer diagnosis and management in primary care, genetic medicine and the conduct of complex interventions trials.

Professor Emery is co-author of a study of the MoleMate system which looked at almost 1300 patients in 15 practices. "Worldwide, the incidence of melanoma is increasing faster than any other cancer, with an approximate doubling of rates every 10 to 20 years in countries with white populations," Professor Emery said.

"In Britain, for example, the incidence of melanoma has quadrupled over the past 40 years. Early detection is critical in reducing mortality and morbidity from melanoma, as the stage 1 disease has five-year survival rates of more than 95 per cent compared with 10-20 per cent for stage 4 of the disease. As pigmented lesions are commonly seen in primary care consultations, GPs need to be able to reassure people with benign lesions and rapidly refer those with suspicious lesions."

Published in the British Medical Journal, the study found that GPs believed the device improved their diagnostic accuracy when it actually performed no better than checklists that suggest GPs look for signs such as the size, colour and shape of lesions and any inflammation, oozing or change in sensation.

"By being perceived more positively, MoleMate provided false reassurance," Professor Emery said. "In fact, the systematic application of best practice guidelines proved more accurate."

The MoleMate system is said to be easier to learn than dermoscopy and predicts melanoma based on images of the epidermal and dermal melanin and vasculature, and the collagen content of the lesion. However, the researchers found the systematic application of best-practice guidelines, including recommended checklists, was the best way to manage suspicious-looking in .

Explore further: Shave biopsy is a safe and acceptable method for initial evaluation of melanoma

More information: www.bmj.com/content/345/bmj.e4110

Related Stories

Shave biopsy is a safe and acceptable method for initial evaluation of melanoma

May 23, 2011
A shave biopsy is a reasonably safe and accurate method for the initial diagnosis of melanoma, according to a study published in the April issue of the Journal of the American College of Surgeons. In the past, some physicians ...

Melanoma screening by physicians associated with finding more cancers than patient self-detection

July 18, 2011
Physician-based screening for melanoma is associated with higher rates of physician-detected melanoma and detection of thinner melanoma, according to a report published Online First today by Archives of Dermatology, one of ...

Risk of second primary melanoma up in pediatric patients

June 28, 2012
(HealthDay) -- Pediatric patients diagnosed with an invasive cutaneous melanoma have nearly double the relative risk of developing a subsequent primary melanoma, compared with adults, according to a study published online ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.